Keywords: Boehringer Ingelheim, USA, Investment, Drug discovery, Manufacturing
Boehringer Ingelheim invests over $350 million in 2011 US expansion projects
Article | 17 November 2011
Privately-held German drug major Boehringer Ingelheim says that it has made more than $350 million worth of capital investments throughout its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
